Medtronic Stock Builds Momentum On AI, SPR Deal And Bullish Street

Medtronic plc gained as stocks have been trading up by 2.11 percent following upbeat sentiment on its latest medical device developments.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MDT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For MDT Traders

Completed $650M SPR Therapeutics acquisition, adding peripheral nerve stimulation assets and modest near‑term earnings drag with longer‑term EPS accretion expectations.
AMA CPT review of renal denervation codes seen as a clear positive, setting up potential reimbursement and adoption tailwinds for Medtronic’s Simplicity Spyral system.
Multiple Wall Street firms kept bullish stances on MDT, with BTIG and Evercore reaffirming Buy/Outperform ratings despite only slight price target tweaks.
TD Cowen trimmed its MDT target to $100 from $119 but maintained a Buy rating, still leaning on CAS growth to offset limited TAVR pressure.
New Touch Surgery Aide AI platform and first real‑time AI app for the Hugo robot highlight Medtronic’s push into higher‑margin, software‑driven surgical technology.

Live Update At 09:17:40 EDT: On Tuesday, July 28, 2026 Medtronic plc. stock [NYSE: MDT] is trending up by 2.11%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MDT has been grinding higher in late July. From 2026/07/06 through 2026/07/27, Medtronic shares climbed from about $83 to close near $84, with several tight trading days between $81 and $85. That is a slow, controlled uptrend, not a meme spike. For short‑term traders, it signals steady dip‑buying and support showing up on every pullback into the low $80s.

Intraday, the most recent 5‑minute data show MDT changing hands around $85–$86 in early trading, slightly above the multi‑day closes. That hints at bullish follow‑through as traders respond to the SPR Therapeutics deal and AI headlines.

Fundamentally, Medtronic is a large, stable cash‑flow machine. Revenue sits near $36.36B annually, with profit margins in the low‑teens and a price‑to‑earnings ratio around 21.6 — not cheap, not stretched. A current ratio of 2.1 and total debt‑to‑equity of 0.57 suggest balance‑sheet strength, giving MDT room to keep funding deals like SPR.

More Breaking News

Free cash flow of roughly $2.09B last quarter and a dividend yield above 3% reinforce that Medtronic still throws off cash while it spends on R&D and acquisitions. For traders, that backdrop often supports buy‑the‑dip setups rather than panic flushes when headlines turn noisy.

Why Traders Are Watching MDT Right Now

MDT is back on a lot of radar screens because the company finally lined up several meaningful catalysts instead of just slow, defensive growth. First, Medtronic closed its $650M cash acquisition of SPR Therapeutics. The Street’s initial reaction was positive — MDT traded up about 1% in premarket action after the announcement, a key tell that traders view the deal as smart, not desperate.

SPR brings short‑term percutaneous peripheral nerve stimulation products for both chronic and acute pain. That plugs straight into Medtronic’s neuromodulation and pain‑management franchise, where procedure growth tends to be higher than in some of its more mature lines. Management expects the acquisition to be only minimally dilutive to adjusted EPS in fiscal 2027 and then neutral to accretive after that. In trading terms, MDT is spending today’s cash for a realistic shot at tomorrow’s higher‑margin growth.

On top of the deal, Medtronic is rolling out Touch Surgery Aide, an NVIDIA‑based real‑time AI compute platform for operating rooms, plus its first FDA‑cleared real‑time AI application for the Hugo robotic system. That gives MDT an angle in AI‑driven surgery — a narrative the market understands and often rewards with higher multiples if execution is solid.

The regulatory setup is also improving. Leerink flagged the AMA CPT Editorial Panel’s decision to review Category I codes for renal denervation as a clear positive for Medtronic’s Simplicity Spyral system. Better codes can mean better reimbursement, which usually leads to higher procedure volumes. Traders should keep an eye on those CPT decisions; they can flip a “nice story” into real revenue momentum.

Layer on the analyst backdrop and the picture sharpens. BTIG nudged its MDT target to $91 and reiterated a Buy, pointing to MedTech sector stabilization and upside if upcoming earnings confirm steady utilization. Evercore ISI trimmed its target to $105 from $106 but held an Outperform call, citing healthy procedure and capex trends. TD Cowen did drop its target from $119 to $100, yet it kept a Buy rating and highlighted strong CAS growth with only modest TAVR headwinds, which are a small slice of Medtronic’s total revenue.

None of these targets scream “moonshot,” but together they say the Street broadly likes MDT’s setup even after resetting expectations.

Conclusion

For active traders, MDT is not a story of wild swings. It is a slow‑burn setup where fundamentals, catalysts, and price action are finally lining up at the same time. Medtronic’s chart shows a controlled move from the high $70s and low $80s into the mid‑$80s while volume and news both picked up. That combination often precedes bigger trend legs if future headlines confirm the thesis.

Those upcoming catalysts are clear. Traders will be watching the next earnings release, already scheduled for fiscal Q1 2027, for updates on SPR Therapeutics integration, traction for Touch Surgery Aide and the Hugo AI application, and early reads on renal denervation reimbursement momentum. If Medtronic shows that cash flow remains strong while these growth bets gain traction, the current analyst targets in the $90–$105 band keep a measured upside narrative alive.

There is also a softer piece to the story. Medtronic’s recent “Medtronic Spark” event brought more than 200 fifth‑grade students into its headquarters for hands‑on health‑tech learning, backed by hundreds of employee volunteers. That will not move this quarter’s numbers, but it speaks to a culture focused on STEM talent and long‑term brand strength — the kind of backdrop that helps large platforms like MDT sustain innovation cycles.

For traders, the playbook here is about preparation, not prediction. As Tim Sykes loves to remind his community, “The market rewards disciplined preparation far more than bold predictions.” And it pairs naturally with another core trading principle: As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.”. MDT is giving you a clear calendar, clear catalysts, and a steady trend. The work now is studying the chart, knowing your key levels, planning your risk, and being ready to react when the next Medtronic headline hits the tape.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!